Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RapMed-2003
- Development stage
- Unknown
- Lead developer
- RAPHAS
- Modality
- Small Molecules, Peptides, Hydrogel Systems → Drug Delivery Systems
- Administration
- Transdermal
01
Overview
RapMed-2003 is a GLP-1 receptor agonist delivered via a dissolving microneedle patch, currently under development by RAPHAS for the treatment of type 2 diabetes and obesity. The product utilizes a semaglutide analog formulated into RAPHAS's proprietary microneedle technology, which allows for transdermal delivery of the medication as an alternative to subcutaneous injections. A Phase 1 clinical trial in 30 subjects was completed in late 2024, evaluating the safety, tolerability, and pharmacokinetic profile of the patch formulation.
- Other names
- Semaglutide analog
02
Targets
Beyond the preview
Go deeper on RapMed-2003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RapMed-2003.